Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus - Wikidata - wikimedia - TriplyDB

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

http://www.wikidata.org/entity/Q39776237

about

Obstructing toxin pathways by targeted pore blockage Recent progress in structure-based anti-influenza drug design M2 protein from influenza A: from multiple structures to biophysical and functional insights Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus New small-molecule drug design strategies for fighting resistant influenza A Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine An assay suitable for high throughput screening of anti-influenza drugs Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.Paramagnetic Cu(II) for probing membrane protein structure and function: inhibition mechanism of the influenza M2 proton channel.Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.Influenza virus m2 ion channel protein is necessary for filamentous virion formation.Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A Coexistence of two adamantane binding sites in the influenza A M2 ion channel.Proton and cation transport activity of the M2 proton channel from influenza A virus.An efficient, optimized synthesis of fentanyl and related analogs.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives New treatments for influenza Functional reconstitution of influenza A M2(22-62).Human monoclonal ScFv that bind to different functional domains of M2 and inhibit H5N1 influenza virus replication.Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors.Viral miniproteins Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity Bakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation.Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.Transmembrane communication: general principles and lessons from the structure and function of the M2 proton channel, K⁺ channels, and integrin receptors.Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.Antiviral strategies against influenza virus: towards new therapeutic approaches.Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel.Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited.Development and identification of a new Vero cell-based live attenuated influenza B vaccine by a modified classical reassortment method.Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction.An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.

P2860

Q26827489-7AD8F3A4-3717-45FE-83F0-04BE9B1764E2 Q26863710-2ED175F0-0295-4BC5-94DD-4CC83AD79D23 Q26991579-69FA208C-E4CA-4D51-8ED0-91211DCD4585 Q27673286-C9CA92A3-780F-495B-8DD2-8C619739A311 Q27675846-B6046703-363D-4D82-9273-144293EF8EFB Q28080554-5C302460-E194-4393-A48E-3B798299E2A3 Q28478569-63E36FD9-050A-4EA6-B5C6-37A6862491A9 Q28484953-BF1A5EB6-F4A9-4316-BB33-17E2610C6969 Q28485914-F663E0EC-F3E7-4684-AA82-F7B4EB41BC5C Q30369353-44DF74EB-E99D-459A-9268-4CFCA361B4DD Q30415676-11DFA2F2-3B18-49CC-9C6B-95C3E185352E Q30427556-309971F1-6267-479B-A313-98E7183294EC Q33826913-5321634B-AC99-4972-B701-3376692FDBEA Q34023430-D7D87C0D-6BCA-42F0-968F-EC26288B19CC Q34068392-F81AE57A-DBF1-4B63-881E-7DCAA6220B64 Q34100507-A270E49E-59CE-4A8B-AC98-B7AE222B909F Q34215292-EC16A744-E5C3-4613-83C0-FF8D96062F15 Q34329204-2372BDEF-945C-4721-8AB7-8BBB00135834 Q34413797-87F1D04B-A8F0-4203-81DE-2CA77D065679 Q34420205-045967C8-A947-45FE-96AD-79B678F2F3F2 Q34721639-25C4BA01-A1C0-4B90-93F3-445C3C1D5F74 Q34864675-8DE81D12-1F3A-4FE8-AAFE-4D4416747FCD Q35151120-7A2B8CFE-2559-4F00-B4B3-0CE5AA6F95CC Q36193000-EC255C66-F3C9-4E3A-B11A-A20FFF4B889B Q36282965-AA234726-03FE-4032-9617-E3A781BD2A1C Q36791678-15B67187-73CE-465D-95C4-7061993FDACB Q37156475-51970CAB-D3AC-4CE4-B60E-8FC6B1E9210D Q37830140-1B3BCCF3-64E0-4F61-8BBA-6B8595EFB046 Q38202012-0476B081-55DD-473E-AB74-F8DB92DCBF33 Q38291733-26F79088-DA50-4C2D-B351-F8106FA2EA1F Q38452544-A5742E7D-C926-47A4-98C1-7EDBDAE4147B Q38770144-6120BC19-5C6D-401B-8B13-644C9550600C Q38952446-FBA5EF72-D56A-4868-A0C7-D7B0E9879331 Q40172861-7F5B4A97-200F-419D-BCAE-EAA29781B7A6 Q40231604-2F9E7EAD-58FA-4E82-9F82-CB29DE288342 Q40238930-28D38070-229D-48BD-B48E-87B769C2BFF2 Q40338821-C38C2BB3-0558-4180-B04C-A846B32F196A Q40372317-7E305E5E-2397-41FA-B035-1F5B31EF50F2 Q40531013-4707FC78-D0BF-4AC9-BC79-337CAD493B8D Q40622883-761A69F3-C671-4AE0-89FC-7EFC73AA439F

P2860

Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus

http://www.wikidata.org/entity/Q39776237

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Design and pharmacological cha ...... n channel of influenza A virus

@en

Design and pharmacological cha ...... channel of influenza A virus.

@nl

type

label

Design and pharmacological cha ...... n channel of influenza A virus

@en

Design and pharmacological cha ...... channel of influenza A virus.

@nl

prefLabel

Design and pharmacological cha ...... n channel of influenza A virus

@en

Design and pharmacological cha ...... channel of influenza A virus.

@nl

P1433

Q39776237-7274288B-C9A3-4878-BFEA-689C6A1DDD41

P1476

Q39776237-A6AFD79D-4C63-4614-9993-02E80CA43271

P2093

Q39776237-0226A22B-6060-45D7-BE95-C8C4F5EFC47D

Q39776237-2FEB68B5-E1F6-4452-8BBE-7405FD26AFA7

Q39776237-3367CA21-9D50-4A99-98FE-AF7765220A90

Q39776237-4900ABD1-6596-4C35-A0B3-345690764A8B

Q39776237-50092206-0F3B-4784-88BA-6B0D0D68FABB

Q39776237-795588AA-640E-4B0A-AC71-0BD8130C3198

Q39776237-D1A96826-E75E-4B7D-B5FB-73FB420AE2AC

P2860

Q39776237-0D0EA5BD-4557-4F0D-84C9-7653A15A6E98

Q39776237-109892F0-9BB0-43CA-A1B1-BEAD540CD882

Q39776237-1F881886-CE19-4E6C-A5A6-892A7AC5EDB3

Q39776237-2AF5A3BA-8783-4BA0-B9E2-1474FE815977

Q39776237-2CD1E203-62D2-43DC-A4D0-55340A4CDCF7

Q39776237-322F10A1-9F7C-47DA-B671-05795E43F5F9

Q39776237-4139FE8E-390A-4D6D-A186-1F663F964D77

Q39776237-4252A12E-FEFC-47E0-A6FF-6189A4BF2605

Q39776237-43FE6794-2E95-4A99-BEDB-A7ADE7C14885

Q39776237-4EFC0D9F-5F11-4D56-9B8A-1C35D8CFF546

P304

Q39776237-43072697-FEEE-474B-B376-019FC05E12F6

P31

Q39776237-5C39A5E0-0ADE-448F-AFA3-C4413FC0D991

P356

Q39776237-FB584375-BCC3-4225-A85E-C783D72FDF89

P407

Q39776237-415A0352-B8D0-42FD-832E-411AAB35AC20

P433

Q39776237-26606768-6145-4313-A1F5-DD9D9D61FBDA

P478

Q39776237-74B9E15D-6DAE-4D68-B23B-798698C1545E

P50

Q39776237-5F075E6F-DCE2-4927-AF81-D74BD1FFDCD7

P577

Q39776237-109F9A98-60AC-4271-AB06-93C4F17AF238

P5875

Q39776237-6CF9474B-025C-4EDB-A6EA-17BB5A48AC31

P698

Q39776237-24A66F9B-BABA-4E1B-9BFE-62FA8B18F7D7

P921

Q39776237-8DDD429D-7722-42A4-99AA-E200E63035C6

P932

Q39776237-9D319CF3-D62C-4D4A-877B-8F6C7333963B

P356

P1433

P1476

Design and pharmacological cha ...... n channel of influenza A virus

@en

P2093

Emma Magavern

http://www.w3.org/2001/XMLSchema#string

Lawrence H Pinto

http://www.w3.org/2001/XMLSchema#string

Robert A Lamb

http://www.w3.org/2001/XMLSchema#string

Victoria Balannik

http://www.w3.org/2001/XMLSchema#string

William F Degrado

http://www.w3.org/2001/XMLSchema#string

Xianghong Jing

http://www.w3.org/2001/XMLSchema#string

Yuki Ohigashi

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and mechanism of the M2 proton channel of influenza A virus

Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel

Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block

Backbone Structure of the Amantadine-Blocked Trans-Membrane Domain M2 Proton Channel from Influenza A Virus

Structural basis for the function and inhibition of an influenza virus proton channel

Structure of Amantadine-Bound M2 Transmembrane Peptide of Influenza A in Lipid Bilayers from Magic-Angle-Spinning Solid-State NMR: The Role of Ser31 in Amantadine Binding

Mechanism of drug inhibition and drug resistance of influenza A M2 channel

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance.

P304

11872-11882

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BI9014488

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38081580

http://www.w3.org/2001/XMLSchema#string

P698

19905033

http://www.w3.org/2001/XMLSchema#string

P921

P932

2794939

http://www.w3.org/2001/XMLSchema#string